February 29, 2024

NEWS RELEASE

Company Name	TMS Co., Ltd.
Name of Representative	Takuro Wakabayashi, President and Representative Director (Code No. 4891 TSE Growth Market)

TMS submits Clinical Trial Plan Notification for TMS-008 Phase I clinical trial in Japan

TMS Co., Ltd. (the "Company") announces today that the Company has submitted a Clinical Trial Plan Notification to the Pharmaceuticals and Medical Devices Agency (“PMDA”) to start Phase I clinical trial (the “Trial") for TMS-008, which is under development for acute kidney injury and other indications.

This is the First-In-Human study of TMS-008, in which TMS-008 will be administered incrementally to healthy adult male subjects to evaluate the pharmacokinetics, pharmacodynamics, and safety of TMS-008. The Trial is scheduled to begin after a 30-day investigation period by the PMDA.

TMS-008 is a small molecule compound belonging to the SMTP (*stachybotrys microspora* triprenyl phenol) compound family derived from black mold, as TMS-007/JX10, expected to have potential as a therapeutic agent for acute kidney injury (AKI) with its anti-inflammatory activity based on soluble epoxide hydrolase (sEH) inhibition as well as antioxidant activity. AKI is an indication in which renal function rapidly declines over a period of hours to days, and no drug has been approved for treatment of AKI to date. AKI can be caused by a variety of reasons, including cardiac surgery and drug side effects. In a study of patients who underwent coronary artery bypass surgery or heart valve surgery, 43% of patients developed acute kidney injury after surgery, and the mortality rate within 30 days was reported to be as high as 20%.[1] Due to these, it is expected there is a significant unmet medical need for effective therapeutic agents for AKI.

This matter will have no impact on the Company’s financial results.

[1] Machado MN, et al. Rev Bras Cir Cardiovasc. 29: 299-307 (2014)

End

Investor and Media Contact:
ir@tms-japan.co.jp